Skip to content

Therapeutic effects of Andiroba oil on oral Wounds induced in children with Cancer under Chemotherapy

Evaluation of the therapeutic effects of Andiroba - carapa guianensis aubl (meliceae) - in induced Oral Mucositis in children with Cancer undergoing Chemotherapy

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
REBEC
Registry ID
RBR-5mhdrh
Enrollment
Unknown
Registered
2020-11-03
Start date
2015-10-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stomatitis

Interventions

The patients were divided into two study groups: Group 1 (laser) (n=30) and Group 2 (andiroba) (n=30). The patients in Group 1 (laser group) were subjected to the OM treatment protocol followed at the
100 mW, power
10 s per lesion
total energy, 0.2 J), in accordance with the manufacturer’s instructions. In the andiroba group, each patient was subjected to four daily applications (every six hours) of the andiroba orabase 3% on
Drug
E07.632.490
E02.190.755

Sponsors

Universidade Federal do Pará
Lead Sponsor
Hospital Ophir Loyola
Collaborator

Eligibility

Age
4 Years to 12 Years

Inclusion criteria

Inclusion criteria: Both genders; volunteers with leukemia; age between four and twelve years; chemotherapy with methotrexate

Exclusion criteria

Exclusion criteria: Recent oral surgery; HIV positive patients.

Design outcomes

Primary

MeasureTime frame
Assessment of decreased oral mucositis scores, verified by the WHO scale method, based on the statistically significant difference (p <0.05) between the groups;Evaluation of the decrease in pain scores, verified by the Wong-Baker visual scale method, based on the statistically significant difference (p <0.05) between the groups

Secondary

MeasureTime frame
Evaluation of the evolution of oral mucositis, using the WHO scale method, based on the statistically significant difference (p <0.05) between the groups;Assessment of pain evolution, using the Wopng-Baker scale method, based on the statistically significant difference (p <0.05) between the groups

Countries

Brazil

Contacts

Public ContactArtur dos Santos Soares

Universidade Federal do Pará

artur_soares_@hotmail.com+55 (91) 98173-4655

Outcome results

None listed

Source: REBEC (via WHO ICTRP)